国恩科技(02768)1月27日至1月30日招股 预计2月4日上市

Core Viewpoint - The company, Guo'en Technology, is set to launch an IPO from January 27 to January 30, 2026, offering 30 million shares globally, with a price range of HKD 34.00 to HKD 42.00 per share, and aims to raise approximately HKD 1.058 billion for expansion and operational purposes [1][5]. Group 1: Company Overview - Guo'en Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [1]. - The company focuses on R&D, production, and sales of industrial and commercial products, catering to manufacturers in downstream sectors such as automotive, new energy, and home appliances [1]. Group 2: Chemical Industry Segment - In the chemical industry, the company has a comprehensive product range that includes upstream green petrochemical materials and midstream organic polymer modified materials [2]. - The company is the second-largest player in China's organic polymer modified materials and organic polymer composite materials market, with a market share of 2.5% as of 2024 [2]. - It is also the largest producer of polystyrene in China by production capacity as of 2024 [2]. Group 3: Health Industry Segment - In the health sector, the company focuses on the natural collagen industry, with a vertical integration strategy that spans from collagen to end products [3]. - The company is the second-largest producer of bone gelatin in China by output and the largest domestic brand in this category as of 2024 [3]. - It ranks as the second-largest domestic brand in the hollow capsule production sector in China by output as of 2024 [3]. Group 4: Investment and Fund Allocation - The company has secured cornerstone investment agreements totaling approximately HKD 320 million, with investors including several financial institutions [4]. - The net proceeds from the IPO are expected to be around HKD 1.058 billion, with allocations planned for expanding production capacity in Thailand (50%), China (35%), and investments in Hong Kong (10%) [5].